The geneticist David Vendrami from Bielefeld University is studying ways in which populations of scallops differ. Photo: Bielefeld University

Biologists at Bielefeld University publish analysis

The scallop is one of the largest edible molluscs, and gourmets consider it to be a great delicacy. To meet this demand, the fishing industry cultivates these shellfish in coastal aquafarms. In a new analysis, behavioural ecologists at Bielefeld University have confirmed that cultivated scallops developed their own genetic structure that differs from that of natural scallops. The biologists studied a total of nine populations of scallops (Pecten maximus) along the coast of Northern Ireland. They are presenting their results this Wednesday (8.2.2017) in the research journal ‘Royal Society Open Science’.

Researchers from VIB, UGent, the Geisel School of Medicine at Dartmouth and several collaborators developed a new antiviral strategy to fight human respiratory syncytial virus (RSV), a leading cause of lower respiratory tract infections in children. The approach hinges on the use of single-domain antibodies, also known as Nanobodies®, which target and neutralize a vital protein in the virus, rendering it unable to enter lung cells. The research, published in the leading scientific journal Nature Communications, elucidates how these Nanobodies® interact with and neutralize the virus and demonstrates their ability to successfully protect mice from RSV infection and related inflammation.

The most common genetic cause of the brain diseases frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) is a mutation in the C9orf72 gene. Researchers from VIB and UAntwerp, headed by Prof. Christine Van Broeckhoven, have demonstrated that if an affected parent passes on this mutation, the children will be affected at a younger age (than the parent). There are no indications that the disease progresses more quickly. These results are published today in the international scientific journal JAMA Neurology.

The newly developed RNAi agent suppressed chronic inflammation in the retinas of diabetic mice. The number of leukocytes (arrows) in the inflamed vasculature was significantly reduced in the RNAi-treated retina (right) comparing to the control experiment (left). (Kanda A. et al., Molecular Therapy: Nucleic Acid, January 12, 2017)

Scientists have developed a new RNA interference (RNAi) therapeutic agent that safely blocked ocular inflammation in mice, potentially making it a new treatment for human uveitis and diabetic retinopathy. Inflammation plays a central role in vision-threatening eye diseases such as age-related macular degeneration and diabetic retinopathy. More commonly, it causes uveitis, or inflammation of the uvea, the pigmented middle layer of the eye. Uveitis causes redness, pain and blurred vision, requiring urgent treatment to prevent complications, including blindness.

Graphene electronic structure represented by the Dirac cone. Using the metaphor of a sandglass- shaped cocktail glass, the differences in the electronic structures are shown as filling of the glass by a liquid made of electrons. Applying negative voltage is equivalent to drinking, and positive voltage to filling the glass with more liquid (=electrons). The Fermi level is the maximum level where you can find electrons, while the slimmest part of the sandglass is called Dirac point. (Graphics were modified from Freepiks)

Graphene's unusual electronic structure enables this extraordinary material to break many records of strength, electricity and heat conduction. Physicists at the Center for Theoretical Physics of Complex Systems (PCS), in collaboration with the Research Institute for Standards and Science (KRISS), used a model to explain the electronic structure of graphene measured by a new spectroscopic platform. These techniques, published in the journal Nano Letters, could promote future research on stable and accurate quantum measurements for new 2D electronics.

Professor Kjetil Taskén is the head of Centre for Molecular Medicine Norway. He is standing next to a robot that can check different cancer drugs on tissue samles from patients. Photo: Bjarne Roesjoe/UiO

The aim is to identify precisely the one drug, or the correct combination of drugs, that are most effective against the specific tumor present in each patient. Professor hopes that new tools will come into use in the next five years. Modern cancer therapy is like searching two hay stacks simultaneously: for the one, special treatment amongst many – to treat one, special tumor out of many.

Nagoya University-led research identifies role for neuronal protein interaction in preventing frontotemporal lobar degeneration, a dementia that starts in middle age. Frontotemporal lobar degeneration (FTLD) is a type of dementia characterized by personality changes, language dysfunction, and abnormal behavior. It has an earlier onset than Alzheimer’s disease, and is associated with a buildup of the tau protein in affected nerve cells (neurons).

Scientists can predict in the lab whether a drug will be effective for individual colorectal tumors

Colorectal carcinomas arise in different forms, so all treatments do not work for all patients. OncoTrack, a public-private consortium supported by the Innovative Medicines Initiative Joint Undertaking, has conducted one of Europe’s largest collaborative academic-industry research projects to develop and assess novel approaches for identification of new markers for colon cancer.

Stando ai dati raccolti dalla sonda MESSENGER i depositi d'acqua ghiacciata nascosti nelle profondità dei crateri di Mercurio proverrebbero dalle comete nate nella cintura di Kuiper. Il liquido si sarebbe solidificato con le basse temperature raggiungendo uno spessore di 50 metri

The USCGC Polar Star escorts a tanker through the sea ice of McMurdo Sound.

Port call holds promise of assisting U.S. Antarctic Program cargo operations

New Zealand has granted the United States permission for a U.S. Coast Guard icebreaker, the USCGC Polar Star, to visit the port of Lyttelton later this month. The icebreaker will make the port call on its way to its home port of Seattle after completing a resupply mission supporting the U.S. Antarctic Program (USAP), which is managed by the National Science Foundation (NSF). The U.S. embassy in Wellington announced the port call earlier this week.